File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Mitomycin chemotherapeutic pleurodesis to palliate malignant pleural effusions secondary to gynecological cancer

TitleMitomycin chemotherapeutic pleurodesis to palliate malignant pleural effusions secondary to gynecological cancer
Authors
KeywordsGynecological malignancy
Mitomycin
Palliation
Pleurodesis
Issue Date1999
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1600-0412
Citation
Acta Obstetricia Et Gynecologica Scandinavica, 1999, v. 78 n. 5, p. 443-446 How to Cite?
AbstractBackground. To assess the efficacy of mitomycin pleurodesis in women with end stage malignant effusion. Methods. Retrospective analysis. Results. Of the 13 patients treated six had ovarian, six had endometrial and one had cervical adenocarcinoma. The median time of onset of effusion from diagnosis of primary disease was 12 months (range 1-75). Ten patients were evaluable for response. The median age of the patients was 59 years (range 42 to 74). Ten (77%) of them had repeated thoracocentesis prior to mitomycin pleurodesis. The median duration and volume of drainage was 4 days (range 2-11) and 3.1 liters (range 1.2-10.2) respectively. One of two patients developed a pneumothorax and required the insertion of an additional chest drain. Overall, seven patients (70%) responded - one completely (CR) and six partially (PR), while three did not respond. Four of five patients with ovarian cancer had a partial response, two of four patients with endometrial cancer (one CR and one PR) responded. The only patient with cervical cancer had a partial response. Nine patients (69%) had enough symptomatic improvement to be discharged home. The drug cost of bleomycin 60 units (US$191), another commonly used agent, was more than twice as expensive as mitomycin 30 mg (US$84). Conclusions. Mitomycin pleurodesis can palliate 70% of patients for at least 1 month. It offers cheap and effective palliation. There is a suggestion that patients' quality of life is improved.
Persistent Identifierhttp://hdl.handle.net/10722/87258
ISSN
2015 Impact Factor: 2.191
2015 SCImago Journal Rankings: 1.197
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCheng, Den_HK
dc.contributor.authorChan, YMen_HK
dc.contributor.authorNg, TYen_HK
dc.contributor.authorCheung, ANYen_HK
dc.contributor.authorNgan, HYSen_HK
dc.contributor.authorWong, LCen_HK
dc.date.accessioned2010-09-06T09:27:22Z-
dc.date.available2010-09-06T09:27:22Z-
dc.date.issued1999en_HK
dc.identifier.citationActa Obstetricia Et Gynecologica Scandinavica, 1999, v. 78 n. 5, p. 443-446en_HK
dc.identifier.issn0001-6349en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87258-
dc.description.abstractBackground. To assess the efficacy of mitomycin pleurodesis in women with end stage malignant effusion. Methods. Retrospective analysis. Results. Of the 13 patients treated six had ovarian, six had endometrial and one had cervical adenocarcinoma. The median time of onset of effusion from diagnosis of primary disease was 12 months (range 1-75). Ten patients were evaluable for response. The median age of the patients was 59 years (range 42 to 74). Ten (77%) of them had repeated thoracocentesis prior to mitomycin pleurodesis. The median duration and volume of drainage was 4 days (range 2-11) and 3.1 liters (range 1.2-10.2) respectively. One of two patients developed a pneumothorax and required the insertion of an additional chest drain. Overall, seven patients (70%) responded - one completely (CR) and six partially (PR), while three did not respond. Four of five patients with ovarian cancer had a partial response, two of four patients with endometrial cancer (one CR and one PR) responded. The only patient with cervical cancer had a partial response. Nine patients (69%) had enough symptomatic improvement to be discharged home. The drug cost of bleomycin 60 units (US$191), another commonly used agent, was more than twice as expensive as mitomycin 30 mg (US$84). Conclusions. Mitomycin pleurodesis can palliate 70% of patients for at least 1 month. It offers cheap and effective palliation. There is a suggestion that patients' quality of life is improved.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1600-0412en_HK
dc.relation.ispartofActa Obstetricia et Gynecologica Scandinavicaen_HK
dc.subjectGynecological malignancyen_HK
dc.subjectMitomycinen_HK
dc.subjectPalliationen_HK
dc.subjectPleurodesisen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGenital Neoplasms, Female - complicationsen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshMitomycins - administration & dosageen_HK
dc.subject.meshPalliative Careen_HK
dc.subject.meshPleural Effusion, Malignant - etiology - therapyen_HK
dc.subject.meshPleurodesisen_HK
dc.subject.meshRetrospective Studiesen_HK
dc.titleMitomycin chemotherapeutic pleurodesis to palliate malignant pleural effusions secondary to gynecological canceren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1936-0851&volume=78&spage=443&epage=446&date=1999&atitle=Mitomycin+chemotherapeutic+pleurodesis+to+palliate+malignant+pleural+effusions+secondary+to+gynecological+canceren_HK
dc.identifier.emailCheung, ANY:anycheun@hkucc.hku.hken_HK
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_HK
dc.identifier.authorityCheung, ANY=rp00542en_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid10326892-
dc.identifier.scopuseid_2-s2.0-0032942626en_HK
dc.identifier.hkuros41790en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032942626&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume78en_HK
dc.identifier.issue5en_HK
dc.identifier.spage443en_HK
dc.identifier.epage446en_HK
dc.identifier.isiWOS:000080141900018-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridCheng, D=7402806161en_HK
dc.identifier.scopusauthoridChan, YM=7403676661en_HK
dc.identifier.scopusauthoridNg, TY=7402229853en_HK
dc.identifier.scopusauthoridCheung, ANY=54927484100en_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK
dc.identifier.scopusauthoridWong, LC=7402092003en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats